This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis. Typical clinical measures and quality of life will be prospectively followed in 12 months period.
Study Type
OBSERVATIONAL
Enrollment
55
Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
Unnamed facility
Many Locations, Poland
Changes of the exercise capacity as measured by 6-minutes walking distance
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes of depression score over time
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes of functional capacity as measured by WHO classification system
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes of pulmonary haemodynamics
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes of serum level of natriuretic peptide B
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes of Quality of Life score
Time frame: 3, 6, 9 and 12 months vs. baseline
Changes in cardiac echo parameters
Time frame: 3, 6, 9 and 12 months vs. baseline
Number of patients with treatment-emergent adverse events
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.